North Macedonia - Pharmaceutical articles - Medicines for the Treatment of Rare Diseases in the Republic of Macedonia for the Period May 2026 - December 2028

Medicines for the Treatment of Rare Diseases in the Republic of Macedonia for the Period May 2026 - December 2028 N07XX06 tetrabenazine 25 mg tablet - tablet; M01CC01 penicillamine 250 mg tablet/capsule - tablet/capsule; A16AX05 zinc acetate 50 mg hard capsule - capsule; N07XX08 tafamidis 20 mg soft capsule - capsule; N07XX02 riluzole 50 mg film-coated tablet - tablet; A16AX06 miglustat 100 mg hard capsule - capsule; A16AB12 elosulfase alfa 5 mg/5 ml concentrate for solution for infusion - vial; A16AB09 idursulfase 6 mg/3 ml concentrate for solution for infusion - vial; L04AC07 tocilizumab 200 mg/10 ml concentrate for solution for infusion - ampoule; A16AB02 imiglucerase 400 IU powder for concentrate for solution for infusion - vial; B06AC01 human C1-esterase inhibitor 500 IU powder and solvent for solution for injection or infusion - vial with powder + vial with solvent + administration set; G04BE03 sildenafil 20 mg film-coated tablet - tablet; A16AX07 sapropterin 100 mg tablet/powder for oral solution - tablet/sachet; C02DA01 diazoxide 25 mg capsule/hard tablet - capsule/hard tablet; H05AA02 teriparatide 20 mcg/80 mcl solution for injection - pre-filled injection pen; N03AG04 vigabatrin 500 mg film-coated tablet / tablet for oral solution - tablet; L01XE10 everolimus 2.5 mg tablet/dispersible tablet - tablet; A16AX04 nitisinone 5 mg hard capsule - capsule; N03AX17 stiripentol 250 mg hard capsule / powder for oral suspension - hard capsule / powder for oral suspension; G04BE03 sildenafil 50 mg film-coated tablet/tablet - tablet; C02KX01 bosentan 125 mg film-coated tablet - tablet; L01XE18 ruxolitinib 5 mg tablet - tablet; V03AC03 deferasirox 360 mg film-coated tablet - tablet; A16AB11 taliglucerase alfa 200 IU powder for solution for infusion - vial; B02BX05 eltrombopag 50 mg tablet - tablet; B02BD07 coagulation factor XIII 250 IU powder and solvent for solution for injection or infusion - powder and solvent for solution for injection or infusion; L04AA10 sirolimus 1 mg coated tablet - tablet; L04AX05 pirfenidone 267 mg film-coated tablet/capsule - tablet/capsule; A16AX10 eliglustat 84 mg hard capsule - capsule; M09AX07 nusinersen 12 mg/5 ml solution for injection - vial; B01AC21 treprostinil 5 mg/ml solution for infusion (subcutaneous and intravenous use) - vial; A16AB10 velaglucerase alfa 400 IU powder for solution for infusion - vial; B06AC02 icatibant 30 mg/3 ml solution for injection - pre-filled syringe; A16AX12 trientine 200 mg hard capsule - capsule; L01EX09 nintedanib 150 mg soft capsule - capsule; M09AX10 risdiplam 0.75 mg/ml powder for oral suspension - bottle; J06BA01 immunoglobulins, normal human 200 mg/ml solution for injection - vial x 5 ml; J06BA01 immunoglobulins, normal human 200 mg/ml solution for injection - vial x 20 ml; B06AC01 human C1-esterase inhibitor (subcutaneous form) 2000 IU powder and solvent for subcutaneous administration - vial with powder + vial with solvent + set for subcutaneous administration; B06AB01 human hemin 250 mg/10 ml concentrate for solution for infusion - ampoule; L04AC03 anakinra 100 mg/0.67 ml (150 mg/ml) solution for injection - 1 pre-filled syringe x 0.67 ml; H01CB05 pasireotide 40 mg powder and solvent for suspension for injection - vial; N07XX08 tafamidis 61 mg soft capsule - capsule; A16AX18 lumasiran 94.5 mg/0.5 ml solution for injection - vial; G04BX16 tiopronin 300 mg prolonged-release tablet - tablet; G04BX16 tiopronin 100 mg prolonged-release tablet - tablet; M05BX07 vosoritide 0.56 mg powder and solvent for solution for injection - vial; M05BX07 vosoritide 1.2 mg powder and solvent for solution for injection - vial; L01EM03 alpelisib 50 mg film-coated tablet - tablet; L04AC19 satralizumab 120 mg/ml solution for injection - pre-filled syringe; L04AA43 ravulizumab 300 mg/30 ml concentrate for solution for infusion - vial; L04AB01 etanercept 50 mg/ml solution for injection - pre-filled injection pen; A05AX04 maralixibat 9.5 mg/1 ml oral solution - bottle; A16AB04 agalsidase beta 35 mg powder for concentrate for solution for infusion - vial; B06AC01 human C1-esterase inhibitor 1500 IU powder and solvent for solution for injection or infusion - vial with powder + vial with solvent + administration set; N07XX25 omaveloxolone 50 mg hard capsule - capsule; L04AC08 canakinumab 150 mg/1 ml solution for injection - vial/pre-filled injection pen; N03AX26 fenfluramine 2.2 mg/1 ml oral solution - bottle; A16AB17 cerliponase alfa 150 mg/5 ml solution for infusion - vial; R03DX09 mepolizumab 100 mg/1 ml solution for injection - pre-filled pen/syringe; C02KX06 sotatercept 45 mg powder and solvent for solution for injection - vial; M05BX05 burosumab 20 mg/ml solution for injection - vial / pre-filled syringe; A16AX08 teduglutide 1.25 mg powder and solvent for solution for injection - vial; H02AB18 vamorolone 40 mg/ml oral suspension - bottle; L01XX74 belzutifan 40 mg film-coated tablet - tablet; A16AX28 sepiapterin 250 mg oral powder - sachet; A16AX28 sepiapterin 1,000 mg oral powder - sachet; C10AX13 evolocumab 140 mg/1 ml solution for injection - pre-filled pen/syringe; B06AC05 lanadelumab 300 mg/2 ml solution for injection - pre-filled syringe; N07XX18 vutrisiran 25 mg/0.5 ml solution for injection - pre-filled syringe; C01EB25 acoramidis 356 mg film-coated tablet - tablet; M09AX10 risdiplam 5 mg film-coated tablet - tablet